Cargando…

Postlicensure surveillance of human papillomavirus vaccine using the Vaccine Adverse Event Reporting System, 2006–2017

BACKGROUND: The United States Food and Drug Administration (FDA) has licensed three HPV (Human papilloma virus) vaccines. The centers for disease control and prevention (CDC) and advisory committee on immunization practices (ACIP) recommends routine HPV vaccination at age 11 or 12 years. This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neha, Reddy, Subeesh, Viswam, Beulah, Elsa, Gouri, Nair, Maheswari, Eswaran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034135/ https://www.ncbi.nlm.nih.gov/pubmed/32154146 http://dx.doi.org/10.4103/picr.PICR_140_18

Ejemplares similares

Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database
por: Kurian, Anitha, et al.
Publicado: (2018)

Detection of Novel Rotavirus Strain by Vaccine Postlicensure Surveillance
por: Weinberg, Geoffrey A., et al.
Publicado: (2013)

Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States
por: Stokley, Shannon, et al.
Publicado: (2014)

Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007–2012, and Postlicensure Vaccine Safety Monitoring, 2006–2013 — United States
por: Stokley, Shannon, et al.
Publicado: (2013)

Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
por: Hesse, Elisabeth M., et al.
Publicado: (2019)

Active Postlicensure Safety Surveillance for Recombinant Zoster Vaccine Using Electronic Health Record Data
por: Nelson, Jennifer C, et al.
Publicado: (2022)

Postlicensure herpes zoster vaccine effectiveness: systematic review protocol
por: Mbinta, James F, et al.
Publicado: (2021)

Generalisability of vaccine effectiveness estimates: an analysis of cases included in a postlicensure evaluation of 13-valent pneumococcal conjugate vaccine in the USA
por: Link-Gelles, Ruth, et al.
Publicado: (2017)

Licensing Examination and Crash Outcomes Postlicensure in Young Drivers
por: Walshe, Elizabeth A., et al.
Publicado: (2022)

Predictors of adverse drug reactions in geriatric patients: An exploratory study among cancer patients
por: Sneha, S. George, et al.
Publicado: (2019)

Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review
por: Mesfin, Yonatan Moges, et al.
Publicado: (2019)

Statistical Power for Postlicensure Medical Product Safety Data Mining
por: Maro, Judith C., et al.
Publicado: (2017)

2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017
por: Arana, Jorge, et al.
Publicado: (2018)

1050 Evaluation of syncope and related events following vaccination with quadrivalent human papillomavirus vaccine (2006-2013)
por: Lievano, Fabio, et al.
Publicado: (2014)

Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005–2017
por: Yoon, Dongwon, et al.
Publicado: (2020)

Human papillomavirus vaccine-associated premature ovarian insufficiency and related adverse events: data mining of Vaccine Adverse Event Reporting System
por: Gong, Li, et al.
Publicado: (2020)

Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case–control assessment of the vaccine adverse event reporting system (VAERS) database
por: Geier, David A., et al.
Publicado: (2016)

Enhanced passive surveillance of influenza vaccination in England, 2016−2017– an observational study using an adverse events reporting card
por: de Lusignan, Simon, et al.
Publicado: (2019)

Human Prion Disease Surveillance in Washington State, 2006-2017
por: Sánchez-González, Liliana, et al.
Publicado: (2020)

Adverse Events of Vaccination against Hepatitis B Virus in Post-Marketing Surveillance from 2005 to 2017 in Guangdong Province, China
por: Liu, Yu, et al.
Publicado: (2022)

Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States
por: Sonawane, Kalyani, et al.
Publicado: (2021)

Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System
por: Tatang, Collins, et al.
Publicado: (2021)

Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China
por: Pan, Xuejiao, et al.
Publicado: (2022)

Raccoon dog rabies surveillance and post-vaccination monitoring in Lithuania 2006 to 2010
por: Zienius, Dainius, et al.
Publicado: (2011)

A case–control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events
por: Geier, David A., et al.
Publicado: (2014)

A cluster analysis of serious adverse event reports after human papillomavirus (HPV) vaccination in Danish girls and young women, September 2009 to August 2017
por: Ward, Daniel, et al.
Publicado: (2019)

Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
por: Sundaram, Maria E., et al.
Publicado: (2022)

Public Health Surveillance for Adverse Events Following COVID-19 Vaccination in Africa
por: Anjorin, AbdulAzeez Adeyemi, et al.
Publicado: (2022)

Barriers to COVID-19 vaccine surveillance: the issue of under-reporting adverse events
por: Noh, Yunha, et al.
Publicado: (2023)

Active Surveillance of Adverse Events Following Human Papillomavirus Vaccination: Feasibility Pilot Study Based on the Regional Health Care Information Platform in the City of Ningbo, China
por: Liu, Zhike, et al.
Publicado: (2020)

Evaluation of prescribing practices and drug-related problems in chronic kidney disease patients: A cross-sectional study
por: Subeesh, Viswam K., et al.
Publicado: (2020)

Trends in Human Papillomavirus–Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017
por: Liao, Cheng-I., et al.
Publicado: (2022)

Trends in anogenital wart incidence among Tennessee Medicaid enrollees, 2006–2014: The impact of human papillomavirus vaccination
por: Shing, Jaimie Z., et al.
Publicado: (2019)

2013 Trends in anogenital warts incidence: Potential impact of human papillomavirus vaccination, TennCare 2006–2015
por: Shing, Jaimie Z., et al.
Publicado: (2018)

Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017
por: Stefanizzi, Pasquale, et al.
Publicado: (2020)

The Logic of Surveillance Guidelines: An Analysis of Vaccine Adverse Event Reports from an Ontological Perspective
por: Courtot, Mélanie, et al.
Publicado: (2014)

Human papillomavirus vaccine
por: Singhal, Priyanka, et al.
Publicado: (2009)

Post-authorization surveillance of adverse events following COVID-19 vaccines in pregnant persons in the vaccine adverse event reporting system (VAERS), December 2020 – October 2021
por: Moro, Pedro L., et al.
Publicado: (2022)

Adverse Events Following Measles-Mumps-Rubella-Varicella Vaccination and the Case of Seizures: A Post Marketing Active Surveillance in Puglia Italian Region, 2017–2018
por: Stefanizzi, Pasquale, et al.
Publicado: (2019)

Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018
por: Jit, Mark
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ad0sngr2rf75h9cqo7gsu3os94